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ABSTRACT
Objectives: To compare the occurrence of drug-free
remission, functional ability and radiological damage after
4 years of response-driven treatment according to four
different treatment strategies for rheumatoid arthritis
(RA).
Methods: Patients with recent-onset, active RA
(n = 508) were randomly assigned to four different
treatment strategies: (1) sequential monotherapy; (2)
step-up combination therapy; (3) initial combination
therapy with prednisone and (4) initial combination
therapy with infliximab. Treatment was adjusted based on
3-monthly disease activity score (DAS) assessments,
aiming at a DAS (2.4. From the third year, patients with
a sustained DAS ,1.6 discontinued treatment.
Results: In total, 43% of patients were in remission (DAS
,1.6) at 4 years and 13% were in drug-free remission:
14%, 12%, 8% and 18% of patients in groups 1–4,
respectively. The absence of anti-cyclic citrullinated
peptide antibodies, male gender and short symptom
duration were independently associated with drug-free
remission. Functional ability and remission were main-
tained in all four groups with the continuation of DAS-
driven treatment, without significant differences between
the groups. Significant progression of joint damage was
observed in 38% and 31% of patients in groups 3 and 4
versus 51% and 54% of patients in groups 1 and 2
(p,0.05, group 4 versus groups 1 and 2, group 3 versus
group 2).
Conclusions: In patients with recent-onset active RA,
drug-free remission was achieved in up to 18% of
patients. DAS-driven treatment maintained clinical and
functional improvement, independent of the treatment
strategy. Joint damage progression remained significantly
lower after initial combination therapy compared with
initial monotherapy.
During the past two decades, new insights into the
treatment of rheumatoid arthritis (RA) have led to
improved clinical, functional and radiographic
outcomes. The immediate introduction of disease
modifying antirheumatic drugs (DMARD) after
diagnosis resulted in better outcomes than delayed
introduction.1–3 Numerous trials have confirmed
the benefits of initial DMARD combination
therapy, including glucocorticoids or tumour
necrosis factor inhibitors, compared with initial
DMARD monotherapy.4–10 In addition, several
studies have shown that strict monitoring and
control of disease activity leads to significantly
improved outcomes compared with routine care.11–
13 However, loss of tight control leads to reduced
remission rates and increases in the Health
Assessment Questionnaire (HAQ) and disease
activity score (DAS).14 Implementation of these
findings in new studies have resulted in an
increasing percentage of patients with recent-onset
RA actually achieving remission.8 12 Drug-free
remission is rarely reported and to our knowledge,
an attempt to achieve drug-free remission has
never been part of a study protocol.
The BeSt study,7 15 a head-to-head comparison of
four different treatment strategies, combined early
treatment with strict monitoring, aiming at a DAS
of 2.4 or less. Initial combination therapy resulted
in significantly earlier clinical and functional
improvement than initial monotherapy. After
2 years, 42% of patients in all groups had achieved
a DAS of less than 1.6, consistent with clinical
remission.7
From year 2 onwards, treatment strategies were
continued, whereas treatment was still being
adjusted to achieve a DAS of 2.4 or less. The
protocol required patients on low-dose mainte-
nance therapy who achieved a DAS less than 1.6
for at least 6 consecutive months to taper and
discontinue all antirheumatic treatment. Here we
report the follow-up results of clinical and radio-
graphic outcomes, including the occurrence of
drug-free remission and its predictors after 4 years
of treatment in the BeSt study.
PATIENTS AND METHODS
The BeSt study (a Dutch acronym for ‘‘Behandel
Strategiee¨n’’, treatment strategies) was designed
and conducted by Dutch rheumatologists partici-
pating in the Foundation for Applied
Rheumatology Research. The medical ethics com-
mittee at each participating centre approved the
study protocol, including the amendment for the
extension phase, and all patients provided written
informed consent before enrolment and before
continuing in the extension study. Included
patients had recent-onset RA with a disease
duration of 2 years or less, were 18 years of age
or older and had active disease with six or more out
of 66 swollen joints, six or more out of 68 tender
joints, and either an erythrocyte sedimentation
rate of 28 mm/h or greater or a global health score
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of 20 mm or greater on a visual analogue scale of 0–100 mm (0,
best; 100, worst). The detailed inclusion and exclusion criteria
were described previously.15
Treatment protocol
Patients were randomly allocated to one of four treatment
groups: sequential monotherapy (group 1, n = 126); step-up
combination therapy (group 2, n = 121); initial combination
therapy including a tapered high dose of prednisone (group 3,
n = 133) and initial combination therapy including infliximab
(group 4, n = 128). For patients failing on their medication
(defined as a DAS .2.4),16 the treatment protocol described a
number of subsequent treatment steps. Briefly, patients in
group 1 started with methotrexate, then sulphasalazine, then
leflunomide, then methotrexate plus infliximab. Patients in
group 2 also started with methotrexate, then methotrexate plus
sulphasalazine, then methotrexate plus sulphasalazine and
hydroxychloroquine, then methotrexate plus sulphasalazine
and hydroxychloroquine and prednisone, then methotrexate
plus infliximab. Patients in group 3 started with methotrexate
plus sulphasalazine and prednisone (tapered from 60 to 7.5 mg/
day), then methotrexate plus ciclosporin A and prednisone
7.5 mg/day, then methotrexate plus infliximab. Patients in
group 4 started with methotrexate plus infliximab, then
sulphasalazine, then leflunomide. The full treatment protocol
including all steps is described elsewhere.15 If the DAS was 2.4 or
less for at least 6 months, medication was gradually tapered
until one drug (methotrexate in groups 1, 2 and 4, and
sulphasalazine in group 3) was administered at a maintenance
dose. In groups 3 and 4, prednisone and infliximab were always
the first drugs to be tapered. In the extension phase beyond
2 years, patients who achieved a DAS of less than 1.6 for at least
6 consecutive months, while treated with monotherapy in a
maintenance dose, tapered and discontinued all medication. If
the DAS increased above 1.6, the last DMARD was immediately
restarted, and if necessary (DAS .2.4) treatment was subse-
quently increased. The DAS was measured every 3 months by a
trained research nurse who remained blinded to the treatment
received.
Study endpoints and assessments
The primary clinical endpoints were functional ability, mea-
sured by the Dutch HAQ17 and the percentage of patients in
drug-free remission, defined as a DAS of less than 1.6,18 without
antirheumatic therapy. The primary radiographic endpoint was
the change from baseline to 4 years in the total Sharp/van der
Heijde score (SHS), ranging from 0 to 448.19 Radiographs of the
hands, wrists and feet at baseline and after 4 years were scored
independently by two trained readers masked to the patient’s
identity, treatment group and sequence of the films. The mean
score of the two readers was used for the analysis. The
interobserver intraclass correlation coefficient was 0.96.
Progression of joint damage was defined as a change in SHS
greater than the smallest detectable change (SDC), which was
4.6 units.20 The radiographic progression data were also
presented in a cumulative probability plot to visualise progres-
sion in individual patients.21 Radiographic progression in
patients in drug-free remission was also assessed.
Safety
Physical examination and laboratory tests were performed at
each visit; all adverse events were recorded. If adverse events
occurred, the treatment dose was reduced to the lowest
tolerated dose. If a drug was not tolerated, the next step in
the protocol was taken, or the other drug(s) of the combination
were continued. Serious adverse events were defined as any
adverse reaction resulting in any of the following outcomes: a
life-threatening condition or death; a significant or permanent
disability; hospitalisation; or a malignancy, regardless of the
relation to the study treatment. Serious infections were defined
Figure 1 Study flow diagram. Reasons for withdrawal during the extension phase are included in the flow diagram. pat, patient; SAE, serious adverse
event.
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as those leading to hospitalisation or death or requiring
intravenous antibiotic treatment. Rates of serious infections
that occurred during treatment with prednisone or infliximab
were expressed as cumulative exposure adjusted event rates
(number of events/100 patient-years of exposure to prednisone
or infliximab). Before infliximab therapy, all patients were
evaluated for tuberculosis with a purified protein derivative skin
test and chest radiography.
Statistical analysis
A sample size of 468 patients (117 per group) was needed to
ascertain 80% power to detect a difference of at least 0.22 in the
HAQ score after 2 years. The sample size also ensured greater
than 80% power to detect a 20% or greater difference in the
change score of radiological joint damage after 2 years. The
initial cohort was followed longitudinally for 4 years. All
available data were included and analyses were based on the
intent-to-treat principle. We performed longitudinal data
analysis of the HAQ with linear mixed-effects models with
treatment strategy, time and their interaction as fixed effects
and centre as random effect.22 For radiographic progression and
the DAS, the main analysis was a completer analysis because
16% of radiographs and 22% of DAS measurements at 4 years
were missing. For the DAS, a last observation carried forward
(LOCF) analysis was performed as the secondary analysis.
Multiple logistic regression analyses were performed to identify
independent predictors of drug-free remission at 4 years.
Independent variables were selected from univariate analyses
if p,0.10. Variables with a Gaussian distribution were first
analysed with a one-way analysis of variance (post-hoc least
significant difference test); variables with a skewed distribution
were tested with a Kruskal–Wallis test (post-hoc Mann–
Whitney U test) and categorical variables were analysed by a
x2 test.
RESULTS
At baseline, the four treatment groups were comparable with
respect to demographic and disease characteristics.15 During the
4-year follow-up, a total of 54 patients (11%) across the four
groups withdrew from the study (n = 11, n = 20, n = 14
and n = 9 in groups 1–4, respectively, overall p = 0.08; fig 1).
Furthermore, an additional 70 patients (14%) across the four
groups (n = 19, n = 15, n = 25 and n = 11 in groups 1–4,
respectively, overall p = 0.11) had deviated from the treatment
protocol.
Table 1 Primary outcomes during 4 years follow-up
Sequential
monotherapy
(group1)
Step-up
combination
therapy
(group 2)
Initial
combination with
prednisone
(group 3)
Initial
combination
with infliximab
(group 4) p Value
Mean (SD) improvement in health
assessment questionnaire
compared with baseline
3 Years 0.8 (0.7) 0.7 (0.7) 0.8 (0.8) 0.9 (0.7) 0.66
4 Years 0.8 (0.6) 0.7 (0.8) 0.8 (0.8) 0.8 (0.8) 0.64
Progression of Sharp/van der
Heijde score from baseline to
4 years follow-up
Total score
Mean (SD) 11.7 (17.3) 9.7 (12.8) 6.7 (9.6) 5.4 (9.2)
Median (IQR) 5.0 (1.0–15.8) 5.5 (1.0–13.8) 3.0 (1.0–7.5) 2.5 (0.5–6.5) 0.005{
Erosion score
Mean (SD) 6.0 (8.8) 5.7 (6.8) 3.0 (4.1) 3.0 (5.2)
Median (IQR) 3.0 (0.5–8.5) 3.5 (0.5–10.0) 2.0 (0.5–3.5) 1.5 (0.5–4.0) 0.001*
Narrowing score
Mean (SD) 5.7 (10.0) 4.0 (7.0) 3.7 (6.7) 2.4 (4.6)
Median (IQR) 1.8 (0.0–7.0) 1.0 (0.0–4.5) 1.0 (0.0–3.9) 1.0 (0.0–2.5) 0.17
*p,0.05 for all comparisons of groups 1 and 2 versus groups 3 and 4; {group 1 versus group 2, p = 0.77; group 1 versus group 3,
p = 0.06; group 1 versus group 4, p = 0.002; group 2 versus group 3, p = 0.10; group 2 versus group 4, p = 0.005; group 3 versus
group 4, p = 0.18. IQR, interquartile range.
Figure 2 Cumulative probability distribution of total Sharp/van der
Heijde Score over 4 years of treatment with sequential monotherapy,
step-up combination therapy, initial combination therapy including
prednisone or initial combination therapy including infliximab. The
smallest detectable change was 4.6 Sharp units and is represented by
the horizontal line.
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Primary outcomes
Previously achieved improvements in HAQ score15 were main-
tained, resulting in 4-year improvements from baseline of 20.8,
20.7, 20.8 and 20.8 (overall, p = 0.64) in groups 1–4,
respectively (mean overall improvement of 20.8, table 1). In
the mixed model analysis it was found that there was a
significant difference in improvement of the HAQ with time
between the four groups: the differences between groups 1 and
2 versus groups 3 and 4 were highly significant (p,0.001), the
difference between groups 3 and 4 was also significant
Table 2 Baseline differences between patients who did or did not achieve drug-free remission after 4 years
Drug-free remission
N = 67
No drug-free remission
N = 441 p Value
Age, years 56 (15) 54 (14) 0.45
Men, n (%) 35 (52) 130 (29) ,0.001*
Time from diagnosis to inclusion, weeks (median, IQR) 2 (1–4) 2 (1–5) 0.63
Symptom duration, weeks (median, IQR) 18 (11–33) 24 (14–56) 0.007*
IgM rheumatoid factor negative, n (%) 32 (48) 147 (33) 0.02
Anti-CCP negative, n (%) 38 (57) 144 (36) 0.001*
DAS 4.1 (0.8) 4.5 (0.9) 0.004
HAQ, 0–3 scale 1.2 (0.6) 1.4 (0.7) 0.002
VAS pain (mm) 45 (22) 55 (22) 0.001
VAS disease activity (mm) 55 (19) 61 (23) 0.04
VAS morning stiffness (mm) 54 (24) 60 (24) 0.04
Erosive, n (%) 44 (69) 313 (72) 0.60
Total SHS, 0–448 scale (median, IQR) 3.3 (1.0–6.9) 4.0 (1.5–9.0) 0.18
*Independently associated with drug-free remission after 4 years. Values are the mean (SD) unless indicated otherwise. CCP,
citrullinated peptide; DAS, disease activity score (44 joints); HAQ, health assessment questionnaire; IQR, interquartile range; SHS,
modified Sharp/van der Heijde Score; VAS, visual analogue scale.
Figure 3 Percentage of patients on different treatment steps, including the occurrence of drug-free remission (no disease-modifying antirheumatic
drugs; DMARD) in four different treatment strategies during 4 years of follow-up. AZA, azathioprine; CSA, ciclosporin A; IFX, infliximab; LEF,
leflunomide; MTX, methotrexate; no DMARD, drug-free remission; other, in groups 1–3 patients in treatment steps beyond MTX + IFX, and in group 4
patients treated with SSA, LEF, CSA, gold or AZA, combined with patients who were treated outside the treatment protocol in all groups; pred,
prednisone; SSA, sulphasalazine; step-up combi, patients treated with MTX + SSA (+ hydroxychloroquine + prednisone). See treatment protocol15 for
detailed information on the sequence of treatment steps in the different groups.
Extended report
Ann Rheum Dis 2009;68:914–921. doi:10.1136/ard.2008.092254 917
 group.bmj.com on August 16, 2011 - Published by ard.bmj.comDownloaded from 
(p = 0.04) and the difference between groups 1 and 2 was not
significant (p = 0.18).
Radiographs of the hands, wrists and feet at baseline and after
a 4-year follow-up were available for 425 patients (106 (84%) in
group 1, 96 (79%) in group 2, 108 (81%) in group 3 and 115
(90%) in group 4). After 4 years, the median total SHS
progression was 5.0, 5.5, 3.0 and 2.5 Sharp units in groups 1–
4, respectively (p,0.05 for group 4 versus groups 1 and 2,
table 1). Joint damage progression greater than SDC was
observed in 51%, 54%, 38% and 31% of patients in groups 1–4
(p,0.05 for group 4 versus groups 1 and 2 and for group 3 versus
group 2, fig 2).
Drug-free remission
After 4 years of continued DAS-driven treatment, 43% of
patients were in clinical remission (DAS ,1.6), regardless of
whether they were on or off drugs (50%, 41%, 38% and 42% in
groups 1–4, overall, p = 0.40). LOCF analysis did not change
these results (data not shown). Between months 24 and 48,
drug-free remission was achieved by 20% of all patients (21%,
17%, 16% and 27% of patients in groups 1–4, respectively,
overall, p = 0.10) and was maintained for a mean (SD) duration
of 9 months (6.4). At 4 years, 13% of all patients were still in
drug-free remission (14%, 12%, 8% and 18% of patients in
groups 1–4, respectively, overall, p = 0.14), whereas 36 patients
(8, 6, 10 and 12 in groups 1–4, respectively) restarted
methotrexate or (in group 3) sulphasalazine due to a DAS of
1.6 or greater after on average 5 months. The mean duration of
drug-free remission in the 67 patients still in drug-free remission
at 4 years was 11 months (6.3) and 57 of these 67 patients
(85%) achieved drug-free remission after a continued good
response on the initial treatment.
Sixty-three of the 67 patients in drug-free remission had HAQ
scores of 0.50 or less, which is similar to values of a normal
population.23 Joint damage progression greater than SDC from
baseline to 4 years was seen in 33%, 14%, 20% and 10% of
patients in drug-free remission in groups 1–4 (overall, p = 0.28).
Compared with the patients not in drug-free remission, patients
who achieved drug-free remission had characteristics of milder
RA at baseline (table 2). After multivariate regression, the
absence of anti-cyclic citrullinated peptide (CCP) antibodies
(p = 0.004), male gender (p = 0.02) and short symptom duration
(p = 0.03) were independently associated with drug-free remis-
sion at 4 years. Treatment strategy was not independently
associated with drug-free remission.
Treatment
The treatment goal of a DAS of 2.4 or less was achieved by 81%
of patients at 4 years, without significant differences between
the groups (p = 0.10). LOCF analysis did not change these
results. Of all included patients, after 4 years, 24%, 29%, 29%
and 16% of patients in groups 1–4 were either lost to follow-up,
or had stopped following the treatment protocol.
Twenty-seven per cent, 23%, 48% and 67% of the patients in
groups 1–4, respectively, achieved a DAS of 2.4 or less on the
initial treatment (methotrexate monotherapy in groups 1 and 2,
methotrexate, sulphasalazine and initially high-dose prednisone
in group 3 and methotrexate and infliximab in group 4) at year
4. In groups 3 and 4, the majority of these patients (31% of
patients in group 3 and 48% of patients in group 4) had been
able to taper their medication to DMARD monotherapy or no
DMARD at all (fig 3). On the other hand, at 4 years, 49%, 48%,
23% and 17% of the patients in groups 1–4 had not reached or
had lost the goal of a DAS of 2.4 or less on the initial treatment
and had moved on to subsequent treatment steps in their
respective strategy arm (fig 3).
During 4 years of treatment, 39% of patients in group 1, 11%
in group 2 and 20% in group 3 started with a combination of
methotrexate plus infliximab, and at the end of year 4, 19%, 6%
and 12% of patients in groups 1–3 were still treated with
methotrexate and infliximab, compared with 20% of patients in
group 4 who were still treated with methotrexate plus
infliximab.
During 4 years, 6%, 22%, 99% and 16% of patients in groups
1–4 ever received prednisone therapy. The mean cumulative
prednisone doses administered during 4 years were 177 mg
Table 3 Adverse events and serious adverse events during 4 years follow-up
Group 1 Group 2 Group 3 Group 4 p Value
Adverse events
Any adverse event during 4 years 103 (82) 100 (83) 106 (80) 107 (84) 0.87
Any adverse event in years 3–4 76 (60) 74 (61) 76 (57) 82 (64) 0.72
Infections years 3–4 31 (25) 35 (29) 24 (18) 32 (25) 0.23
Gastrointestinal years 3–4 18 (14) 13 (11) 17 (13) 21 (16) 0.61
Dermal/mucosal years 3–4 16 (13) 16 (13) 18 (14) 12 (9) 0.72
Neurological years 3–4 9 (7) 11 (9) 3 (2) 16 (13) 0.02*
Cardiovascular years 3–4 5 (4) 7 (6) 13 (10) 11 (9) 0.25
Infusion reactions years 3–4 (n) 1 0 1 2 0.58
SAE
Any SAE during 4 years 41 (33) 29 (24) 33 (25) 26 (20) 0.15
Any SAE in years 3–4 26 (21) 21 (17) 15 (11) 19 (15) 0.21
Total SAE during 4 years (n) 57 45 60 47 0.31
Serious infections during 4 years (n) 12 2 5 6 0.03{
Malignancies during 4 years (except non-melanoma skin
cancers, n)
3 4 5 1 0.44
Non-melanoma skin cancers during 4 years (n) 2 0 1 3 0.35
Deaths during 4 years (n) 1 3 1 3 0.53
Values indicate the number (percentage) of patients unless indicated otherwise. *p,0.05 for group 3 versus group 4; {p,0.05 for
group 1 versus group 2. Causes of death per group were the following, in group 1: pneumonia, antibiotic treatment refused (year 3);
group 2: cerebrovascular accident (year 2); bronchial carcinoma and myocardial infarction (both year 4); group 3: ovarian
carcinoma (year 2); group 4: disseminated tuberculosis{24 and myocardial infarction (both year 2); septic arthritis{ (year 3).
{Deaths judged to be possibly related to treatment with infliximab. SAE, serious adverse event.
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prednisone in group 1, 565 mg in group 2, 4116 mg in group 3
(of which 1899 mg was administered during the initial 28-week
period of initial high tapered to low-dose prednisone) and
588 mg in group 4.
Safety
Overall, 82% of patients experienced at least one adverse event
and 25% of patients experienced at least one serious adverse
event (table 3).24 The majority of the adverse events were mild
to moderate and did not result in treatment discontinuation or
dose reduction. Significantly, more serious infections occurred
in group 1 compared with group 2. Under the limitation that
knowledge of treatment currently or recently received may
influence the interpretation of an infection as ‘‘serious’’, we
have looked at the rate of infections and serious infections in
relation to treatment with infliximab and prednisone. We found
that of the 25 serious infections in all groups, 11 episodes
occurred during treatment with infliximab and five during
treatment with prednisone. Total exposure to infliximab was
329.1 patient-years (86.5, 22.1, 39.3 and 181.1 in groups 1–4,
respectively), resulting in a cumulative rate of serious infections
for years 0–4 of 3.3 events/100 patient-years on infliximab
treatment. Total exposure to prednisone was 240.3 patient-
years (9.2, 27.8, 174.8 and 28.5 in groups 1–4, respectively),
resulting in a cumulative rate of serious infections for years 0–4
of 2.1 events/100 patient-years on prednisone treatment.
During 4 years, six cases of non-melanoma skin cancers were
reported; five of these cases developed in patients who had been
treated with infliximab. None of the other malignancies
developed during or after treatment with infliximab. No cases
of tuberculosis were observed during the third and fourth years.
In total, eight deaths occurred during the 4-year follow-up
(table 3).
DISCUSSION
The 4-year follow-up data of the BeSt study show that
continued tight disease control in patients with recent-onset
RA resulted in sustained functional and clinical improvement,
regardless of the treatment strategy. Radiological damage
progression over time is still significantly lower in patients
treated with initial combination therapy including either
prednisone or infliximab (groups 3 and 4) than in patients
treated with initial monotherapy, although the differences were
small. The clinical relevance of these differences will need to be
clarified with longer follow-up, because joint damage is assumed
to have the most impact on disability with longer disease
duration.25 26 Compared with group 1, relatively few patients in
group 2 proceeded to treatment with methotrexate plus
infliximab. Differences in treatments prescribed after metho-
trexate failure,27 including prednisone in group 2 and the
continuous step-up and step-down approaches in group 2 may
have influenced this observation.
For the first time in a large trial in RA patients, the treatment
protocol of the BeSt study provided instructions for the
introduction of drug-free remission. From the third year of the
study, patients who achieved remission (DAS ,1.6) for at least
6 consecutive months, tapered and stopped the last DMARD,
being methotrexate or in some cases sulphasalazine. Drug-free
remission was achieved and maintained in 8–18% of patients
and has lasted until now for an average period of one year,
without significant differences between the four strategies. The
absence of anti-CCP antibodies, male gender and short
symptom duration were independently associated with
drug-free remission. Although in general patients in drug-free
remission appeared to have milder disease characteristics, at
baseline 69% already had erosive disease, 52% were rheumatoid
factor positive, 43% were anti-CCP positive, the mean HAQ
was 1.2 and the mean DAS was 4.1.
Previous studies on remission reported varying percentages of
remission, due to differences in patient enrollment, study
population, definitions of remission and treatment.12 28–30
Drug-free remission in recent-onset RA, however, is seldom
reported as an endpoint of treatment. In a prospective study
involving 135 early RA patients, 32 (5%) of 606 ‘‘DMARD
courses’’ were discontinued because of remission, compared
with 528 courses that were terminated for other reasons.31
Similar low percentages of drug-free remission were also
reported in other studies.32 33 Several studies reported a high
incidence of disease flares as soon as treatment was with-
drawn.34–36 In the BeSt study, the prevalence of drug-free
remission remained remarkably high (12–14% with initial
methotrexate monotherapy, 8% with initial combination
therapy including a tapered high dose of prednisone and 18%
with initial combination therapy including infliximab), taking
into account that in on average 35% of patients who achieved
drug-free remission, treatment was reinitiated because the DAS
increased to 1.6 or greater.
Other studies in early RA indicate that low disease activity or
even remission can be maintained after the discontinuation of
infliximab, but with the continuation of low-dose methotrex-
ate.37–39 This analysis provides further evidence that preservation
of low disease activity for as long as 35 months after infliximab
discontinuation is possible after a relatively short course (mean
9 months) of infliximab induction therapy.
Previous research has shown that in 7–17% of patients with
RA in clinical remission progression of joint damage still
occurs.40 41 We found that 10–33% of patients in drug-free
remission also showed joint damage progression from baseline
to 4 years. As yet, we have no information as to whether
damage progression continued once drug-free remission was
achieved, because we could not read radiographs from all four
timepoints. In the prolonged follow-up of the BeSt study,
blinded radiographs from all timepoints will be read in the same
session. This will help us to determine any changes in the slope
of radiographic progression in the four groups, and will reveal
whether clinically significant damage occurs without clinically
noticeable inflammation.
The percentages of patients experiencing adverse events or
serious adverse events were not significantly different between
the four groups. Due to the dynamic treatment design of the
study, it is possible that some adverse events that occurred
during a specific treatment are actually related to the previous
therapy. The impression that some patients developed serious
infections while they were treated with infliximab or pre-
dnisone could be partly due to expectation bias influencing the
reports. These concerns make it awkward to draw firm
conclusions on the toxicity of the different treatments used,
but at least between the strategies there appears to be no
significant difference in toxicity. All infections responded well
to antibiotic treatment. No malignancies developed during
infliximab treatment, except for five relatively indolent non-
melanoma skin cancers.
In conclusion, tight control using DAS-driven therapy
adjustments leads to prolonged reduction of disease activity
and improvement in functional capacity, irrespective of treat-
ment strategy. Radiological damage progression remains lower
in patients treated with initial combination therapy including
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prednisone or infliximab. These results confirm the importance
of early effective treatment and continued tight control and
demonstrate that once a continuous good clinical response is
achieved, the discontinuation of combination therapy and even
drug-free remission are realistic possibilities in the treatment of
patients with recent-onset active RA.
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